tirzepatide news 2025 New clinical trial: Zepbound (tirzepatide) helped adults lose an average of 20.2% of their body weight—around 50 lbs—over 72 weeks, outperforming Wegovy's 13.7% (~33 lbs). Credit to: https://www.healthline.com/health-news/zepbound-wegovy-weight-loss FDA Says Compounded Tirzepatide Must

Mounjaro has shown greater weight loss outcomes compared to Retatrutide in clinical trials, but both medications offer effective weight management options, with individual considerations influencing the choice between them

Prioritise easily digestible foods such as lean proteins, cooked vegetables, and low-FODMAP options whilst avoiding high-fat meals, cruciferous vegetables, legumes, and carbonated drinks

(2015) "MOTS-c promotes metabolic homeostasis." Published in Cell Metabolism

Nor does it explain another surprising finding from the study: men taking these weight-loss treatments appeared to face three times the risk of vision loss compared to women

Journal of Nutritional Biochemistry, 22(5), 426440

In a study by Drucker et al